secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001558370-24-002189
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics 2023 revenue up 34% to $938M; guides 2024 revenue $600-680M
----------------------------------------------------------------------------

- Total revenue $937.8M (+34% YoY); net loss $626.6M vs $559.0M in 2022.
- DMD franchise: Translarna $356M, Emflaza $255M; Evrysdi royalty + milestone $268.9M.
- Cash and securities $876.7M vs $410.7M a year ago; debt extinguishment loss $137.6M.
- Pipeline: sepiapterin MAA submission in Mar 2024, NDA by Q3 2024; vatiquinone NDA expected late 2024.
- 2024 guidance: total revenue $600-680M (down from $938M); GAAP R&D+SG&A $740-835M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000155837024002189/0001558370-24-002189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000155837024002189/tmb-20240229x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer